IL230487B - 6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them - Google Patents

6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them

Info

Publication number
IL230487B
IL230487B IL230487A IL23048714A IL230487B IL 230487 B IL230487 B IL 230487B IL 230487 A IL230487 A IL 230487A IL 23048714 A IL23048714 A IL 23048714A IL 230487 B IL230487 B IL 230487B
Authority
IL
Israel
Prior art keywords
oxaborol
methylbenzofuran
methylsulfonamido
dihydrobenzo
fluorophenyl
Prior art date
Application number
IL230487A
Other languages
English (en)
Hebrew (he)
Other versions
IL230487A0 (en
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47746761&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL230487(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL230487A0 publication Critical patent/IL230487A0/en
Publication of IL230487B publication Critical patent/IL230487B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL230487A 2011-08-19 2014-01-16 6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them IL230487B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161525440P 2011-08-19 2011-08-19
US201261650681P 2012-05-23 2012-05-23
PCT/US2012/050268 WO2013028371A1 (en) 2011-08-19 2012-08-10 Benzofuran compounds for the treatment of hepatitis c virus infections

Publications (2)

Publication Number Publication Date
IL230487A0 IL230487A0 (en) 2014-03-31
IL230487B true IL230487B (en) 2019-06-30

Family

ID=47746761

Family Applications (1)

Application Number Title Priority Date Filing Date
IL230487A IL230487B (en) 2011-08-19 2014-01-16 6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them

Country Status (38)

Country Link
US (2) US8927593B2 (enExample)
EP (2) EP2744332B1 (enExample)
JP (2) JP6367712B2 (enExample)
KR (1) KR101913800B1 (enExample)
CN (1) CN103732065B (enExample)
AR (1) AR087563A1 (enExample)
AU (1) AU2012299295B2 (enExample)
BR (1) BR112014002845A2 (enExample)
CA (1) CA2844086A1 (enExample)
CL (2) CL2014000393A1 (enExample)
CO (1) CO6862153A2 (enExample)
CR (1) CR20140078A (enExample)
CY (1) CY1118399T1 (enExample)
DK (1) DK2744332T3 (enExample)
DO (1) DOP2014000034A (enExample)
EA (1) EA032841B1 (enExample)
ES (1) ES2611731T3 (enExample)
HR (1) HRP20161743T1 (enExample)
HU (1) HUE030300T2 (enExample)
IL (1) IL230487B (enExample)
IN (1) IN2014CN00572A (enExample)
JO (1) JO3281B1 (enExample)
LT (1) LT2744332T (enExample)
MA (1) MA35443B1 (enExample)
ME (1) ME02588B (enExample)
MX (1) MX354676B (enExample)
PE (1) PE20141201A1 (enExample)
PH (1) PH12014500385A1 (enExample)
PL (1) PL2744332T3 (enExample)
PT (1) PT2744332T (enExample)
RS (1) RS55462B1 (enExample)
SG (1) SG10201606883QA (enExample)
SI (1) SI2744332T1 (enExample)
SM (2) SMT201700028T1 (enExample)
TW (1) TWI538915B (enExample)
UY (1) UY34274A (enExample)
WO (1) WO2013028371A1 (enExample)
ZA (1) ZA201401020B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2735542T3 (es) 2011-08-17 2019-12-19 Glaxosmithkline Llc Procedimientos terapéuticos
US8927593B2 (en) 2011-08-19 2015-01-06 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis C virus infections
US10308937B2 (en) * 2014-11-10 2019-06-04 Glaxosmithkline Intellectual Property (No. 2) Limited Combination long acting compositions and methods for Hepatitis C
CA2967195A1 (en) 2014-11-10 2016-05-19 Glaxosmithkline Intellectual Property (No.2) Limited Long acting pharmaceutical compositions for hepatitis c
KR20180006522A (ko) 2016-07-07 2018-01-18 삼성디스플레이 주식회사 액정 조성물 및 이를 포함하는 액정 표시 장치
US11738088B2 (en) 2016-08-01 2023-08-29 University of Pittsburgh—of the Commonwealth System of Higher Education Boryl ethers, carbonates, and cyclic acetals as oxidatively-triggered drug delivery vehicles
EP3589630B1 (en) * 2017-03-02 2021-07-07 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
MA51611A (fr) * 2018-01-17 2021-04-21 Glaxosmithkline Ip Dev Ltd Inhibiteurs de pi4kiiibêta
EP4049680A4 (en) * 2019-10-25 2024-01-10 Sumitomo Pharma Co., Ltd. NEW SUBSTITUTED CONDENSED RING CONNECTION
CN111026203B (zh) * 2019-12-02 2021-01-26 宁波德晶元科技有限公司 一种适用于真空热水壶的加热控制方法与系统

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
AU5920400A (en) * 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Cell-based assay systems for examining hcv ns3 protease activity
ES2571219T3 (es) 2001-01-25 2024-09-23 The United States Of America Represented By The Sec Dep Of Health And Human Services Formulación de compuestos de ácido borónico
BR0315937A (pt) * 2002-11-01 2005-09-13 Viropharma Inc Composto, composição para a profilaxia ou tratamento de infecções virais, e, método para a profilaxia ou tratamento de infecções da hepatite c e doenças associadas com tais infecções em um hospedeiro vivo
WO2008051244A2 (en) 2005-12-01 2008-05-02 Wyeth Anthranilic acid derivatives useful in treating infection with hepatitis c virus
DK1988779T5 (en) 2006-02-16 2016-10-10 Anacor Pharmaceuticals Inc SMALL boron MOLECULES AS ANTI-INFLAMMATORY AGENTS
CA2651212A1 (en) * 2006-05-02 2007-11-15 Anacor Pharmaceuticals, Inc. Hydrolytically-resistant boron-containing therapeutics and methods of use
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
EP3150589A1 (en) 2007-06-08 2017-04-05 MannKind Corporation Ire-1a inhibitors
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
WO2009111676A2 (en) 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
CN101910145A (zh) * 2008-02-14 2010-12-08 弗·哈夫曼-拉罗切有限公司 抗病毒的杂环化合物
WO2009137500A1 (en) * 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
TW201008933A (en) 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
EP2348863A4 (en) 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
WO2011103063A1 (en) 2010-02-19 2011-08-25 Glaxo Group Limited Therapeutic compounds
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
TW201136919A (en) 2010-03-02 2011-11-01 Merck Sharp & Amp Dohme Corp Inhibitors of hepatitis C virus NS5B polymerase
WO2011106986A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
TW201221518A (en) 2010-11-18 2012-06-01 Glaxo Group Ltd Compounds
WO2012067663A1 (en) 2010-11-18 2012-05-24 Glaxo Group Limited Compounds
ES2735542T3 (es) * 2011-08-17 2019-12-19 Glaxosmithkline Llc Procedimientos terapéuticos
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
US8927593B2 (en) 2011-08-19 2015-01-06 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis C virus infections

Also Published As

Publication number Publication date
EA032841B1 (ru) 2019-07-31
PL2744332T3 (pl) 2017-03-31
BR112014002845A2 (pt) 2017-02-21
TWI538915B (zh) 2016-06-21
CR20140078A (es) 2014-03-20
KR101913800B1 (ko) 2018-11-01
AU2012299295B2 (en) 2016-03-31
US8927593B2 (en) 2015-01-06
JP2017125010A (ja) 2017-07-20
ES2611731T3 (es) 2017-05-10
PE20141201A1 (es) 2014-10-03
IN2014CN00572A (enExample) 2015-04-03
LT2744332T (lt) 2017-01-10
RS55462B1 (sr) 2017-04-28
MA35443B1 (fr) 2014-09-01
CN103732065B (zh) 2016-10-26
CY1118399T1 (el) 2017-06-28
EP2744332B1 (en) 2016-10-26
US20150080343A1 (en) 2015-03-19
JP6367712B2 (ja) 2018-08-01
IL230487A0 (en) 2014-03-31
SMT201700028T1 (it) 2017-03-08
PH12014500385A1 (en) 2020-06-22
MX2014001989A (es) 2014-02-27
AU2012299295A1 (en) 2014-02-20
EP3199531A1 (en) 2017-08-02
CA2844086A1 (en) 2013-02-28
HUE030300T2 (en) 2017-04-28
EP2744332A1 (en) 2014-06-25
WO2013028371A1 (en) 2013-02-28
DK2744332T3 (en) 2017-01-16
CN103732065A (zh) 2014-04-16
MX354676B (es) 2018-03-15
EP2744332A4 (en) 2015-01-14
TW201321390A (zh) 2013-06-01
CL2014000393A1 (es) 2014-08-01
SG10201606883QA (en) 2016-10-28
JO3281B1 (ar) 2018-09-16
CO6862153A2 (es) 2014-02-10
US20130237501A1 (en) 2013-09-12
US9682999B2 (en) 2017-06-20
EA201490213A1 (ru) 2014-07-30
SI2744332T1 (sl) 2017-01-31
PT2744332T (pt) 2017-01-24
HRP20161743T1 (hr) 2017-02-24
DOP2014000034A (es) 2014-06-01
CL2017000293A1 (es) 2017-10-06
AR087563A1 (es) 2014-04-03
SMT201700028B (it) 2017-03-08
ZA201401020B (en) 2020-11-25
ME02588B (me) 2017-06-20
KR20140054287A (ko) 2014-05-08
UY34274A (es) 2013-04-05
JP2014527529A (ja) 2014-10-16

Similar Documents

Publication Publication Date Title
IL230487B (en) 6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them
IL229199A (en) N– (2– {2– dimethylaminoethyl-methylamino} –4 – methoxy-5 - {[4– (1-methylindol-3-yl) pyrimidine-2-yl] amino} phenyl) prop-2-anamide and salts acceptable in pharmacy Her, pharmaceuticals that include her and its use in the manufacture of cancer drugs
IL222878A (en) N - ((2-oxo-2,1-dihydropyridine-3-ram) methyl) -1h-indole-4-carboxamide and pharmaceuticals containing them
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
PL2808325T3 (pl) Podstawione azole, przeciwwirusowy składnik czynny, kompozycja farmaceutyczna, sposób ich wytwarzania i stosowania
IL232914A0 (en) New Azetidine histories, pharmaceutical preparations and their uses
IL223543A (en) Pharmaceutical preparation containing 1– (4– (4– (4,3-dichloro-2 – fluorophenylamino) –7 – methoxyquinazoline – 6 – Iloxy) piperidine – 1 – il) Prof. 2 – an – 1 – on or a common pharmaceutical salt His and an acidic addition
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
IL230484A (en) "6- (n- (7-Chloro-1-Hydroxy-1, 3-Dihydrobenzo [c] [1,2] Oxaborol-5-Yl) - Methylbenzoforan-3 - Carbamamide and a Pharmaceutical Preparation
ZA201405756B (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
ZA201303695B (en) Pharmaceutical composition comprising citrate and bicarbonate salts,and use thereof for treating cystinuria
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
BR112014001425A2 (pt) forma de dosagem farmacêutica, composição farmacêutica, e, composto (i) ou sal farmaceuticamente aceitável do mesmo
IL225105A (en) Heterocyclic compounds, their process, their pharmaceutical preparations and their use in the preparation of drugs
PH12013501509A1 (en) Treatment of cognitive dysfunction in schizophrenia
PT2722322T (pt) Derivado de 1,3-di-oxo-indeno, seu sal farmaceuticamente aceitável ou isómero ótico, seu método de preparação, e composição farmacêutica contendo o mesmo como ingrediente ativo, antiviral
BR112013007904A2 (pt) "composto, composição farmacêutica, medicamento, uso de um composto e proceso para preparar um composto"
MX2013008269A (es) Composicion farmaceutica que comprende derivados de piridona.
PT2476420E (pt) Composição farmacêutica com atividade antimicrobiana e de cicatrização rápida para administração externa, e processo de preparação da mesma
SI3882244T1 (sl) Spojina, farmacevtsko sprejemljiva sol ali optični izomer le-te, postopek za njeno pripravo in farmacevtski sestavek za preprečevanje ali zdravljenje virusnih bolezni, ki jo vsebuje kot učinkovino
EP2386301A4 (en) PHARMACEUTICAL COMPOSITION OF LEVOAMLOPIDINE OR PHARMACEUTICAL ACCEPTABLE SALTS AND BETA BLOCKERS, AND USE THEREOF
IL238071B (en) Pharmaceutical composition of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof for the treatment of cardiovascular disease
BR112012028227A2 (pt) composto representado pela fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, agente terapêutico e/ou profilático para uma doença causada pela formação de trombo
SG11201801423PA (en) Pharmaceutical composition for preventing and treating liver diseases, containing, as active ingredient, cromolyn or pharmaceutically acceptable salt thereof
WO2012108794A3 (ru) Производные 1,2,4-триазол-з-илтиогликолевой кислоты для применения в терапии

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees